SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-22-000067
Filing Date
2022-08-09
Accepted
2022-08-09 16:13:36
Documents
63
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20220630.htm   iXBRL 10-Q 1587756
2 EX-10.1 allo-20220630xex101.htm EX-10.1 18837
3 EX-31.1 allo-20220630xex311.htm EX-31.1 9888
4 EX-31.2 allo-20220630xex312.htm EX-31.2 9858
5 EX-32.1 allo-20220630xex321.htm EX-32.1 7115
  Complete submission text file 0001737287-22-000067.txt   6620920

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20220630.xsd EX-101.SCH 43912
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20220630_cal.xml EX-101.CAL 51029
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20220630_def.xml EX-101.DEF 233206
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20220630_lab.xml EX-101.LAB 579278
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20220630_pre.xml EX-101.PRE 362370
57 EXTRACTED XBRL INSTANCE DOCUMENT allo-20220630_htm.xml XML 1022857
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 221148461
SIC: 2836 Biological Products, (No Diagnostic Substances)